Recombinant anti-CD25 immunotoxin RFT5(scFv)-ETA' demonstrates successful elimination of disseminated human hodgkin lymphoma in SCID mice

International Journal of Cancer

Volumn 86, Issue 5, 2000, Pages 718-724

  Barth, Stefan ^a,b   Huhn, Michael ^a   Matthey, Bärbel ^a   Schnell, Roland ^a   Tawadros, Samir ^a   Schinköthe, Timo ^a   Lorenzen, Johann ^a   Diehl, Volker ^a   Engert, Andreas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; PSEUDOMONAS EXOTOXIN; RECOMBINANT PROTEIN; RICIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ESCHERICHIA COLI; EXPRESSION VECTOR; HODGKIN DISEASE; HUMAN; HUMAN CELL; INOCULATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCID MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; HODGKIN DISEASE; HUMANS; IMMUNOTOXINS; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS;

EID: 0034061246     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000601)86:5<718::AID-IJC18>3.0.CO;2-N     Document Type: Article

References (20)

1. ̇ Hodgkin-derived cell lines. Int. J. mol. Med. 1, 249-256 (1998).
2. BARTH, S., SCHNELL, R., DIEHL, V. and ENGERT, A., Development of immunotoxins for potential clinical use in Hodgkin's disease. Ann. Oncol., 7(Suppl. 4), 135-141 (1996).
3. BUCHNER, J., PASTAN, I. and BRINKMANN, U., A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from re-naturation of bacterial inclusion bodies. Anal. Biochem., 205, 263-270 (1992).
4. DOWER, W., Electroporation of bacteria: a general approach to genetic transformation. Genet. Eng., 12, 275-295 (1990).
5. ENGERT, A. and 14 OTHERS, A phase-I study of an anti-CD25 ricin-A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood, 89, 403-410 (1997).
6. ENGERT, A., MARTIN, G., AMLOT, P., WIJDENES, J., DIEHL, V. and THORPE, P., Immunotoxins constructed with anti-CD25 monoclonal antibodies and de-glycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice. Int. J. Cancer, 49, 450-456 (1991).
7. KAPP, U., WOLF, J., VON, K.C., TAWADROS, S., ROTTGEN, A., ENGERT, A., FONATSCH, C., STEIN, H. and DIEHL, V., Preliminary report: growth of Hodgkin's-lymphoma-derived cells in immune compromised mice. Ann. Oncol., 3(Suppl. 4), 21-23 (1992).
8. KLIMKA, A., BARTH, S., DRILLICH, S., WELS, W., VAN, S.J., RENAULD, J., TESCH, H., BOHLEN, H., DIEHL, V. and ENGERT, A., A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA′) shows specific cytotoxicity against IL-9-receptor-expressing cell lines. Cytokines mol. Ther., 2, 139-146 (1996).
9. KLIMKA, A., BARTH, S., MATTHEY, B., ROOVERS, R.C., LEMKE, H., HANSEN, H., ARENDS, J.W., DIEHL, V., HOOGENBOOM, H.R. and ENGERT, A., An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA′) is a potent immunotoxin against a Hodgkin-derived cell line. Brit. J. Cancer, 80, 1214-1222 (1999).
10. KREITMAN, R. and PASTAN, I., Recombinant single-chain immunotoxins against T- and B-cell leukemias. Leuk. Lymphoma, 13, 1-10 (1994).
11. KREITMAN, R. and PASTAN, I., Targeting Pseudomonas exotoxin to hematologic malignancies. Semin. Cancer Biol., 6, 297-306 (1995).
12. KREITMAN, R., WANG, Q., FITZGERALD, D. and PASTAN, I., Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int. J. Cancer, 81, 148-155 (1999).
13. LEMAISTRE, C., SALEH, M., KUZEL, T., FOSS, F., PLATANIAS, L., SCHWARTZ, G., RATAIN, M., ROOK, A., FREYTES, C., CRAIG, F., REUBEN, J. and NICHOLS, J., Phase-I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood, 91, 399-405 (1998).
14. MATTHEY, B., ENGERT, A., KLIMKA, A., DIEHL, V. and BARTH, S., A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins. Gene, 229, 145-153 (1999).
15. MCCAFFERTY, J., FITZGERALD, K., EARNSHAW, J., CHISWELL, D., LINK, J., SMITH, R. and KENTEN, J., Selection and rapid purification of murine antibody fragments that bind a transition-state analog by phage display. Appl. Biochem. Biotechnol., 47, 157-171 (1994).
16. MERZ, H., MALISIUS, R., MANNWEILER, S., ZHOU, R., HARTMANN, W., ORSCHESCHEK, K., MOUBAYED, P. and FELLER, A., ImmunoMax. A maximized immunohistochemical method for the retrieval and enhancement of hidden antigens. Lab. Invest., 73, 149-156 (1995).
17. REITER, Y., PAI, L., BRINKMANN, U., WANG, Q. and PASTAN, I., Anti-tumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res., 54, 2714-2718 (1994).
18. SAMBROOK, J., FRITSCH, E. and MANIATIS, T., Molecular cloning. A laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press, New York (1989).
19. SCHNELL, R., VITETTA, E., SCHINDLER, J., BARTH, S., WINKLER, U., BORCHMANN, P., HANSMANN, M.L., DIEHL, V., GHETIE, V. and ENGERT, A., Clinical trials with an anti-CD25 ricin-A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Leuk. Lymphoma, 30, 525-537 (1998).
20. WINKLER, U., GOTTSTEIN, C., SCHON, G., KAPP, U., WOLF, J., HANSMANN, M., BOHLEN, H., THORPE, P., DIEHL, V. and ENGERT, A., Successful treatment of disseminated human Hodgkin's disease in SCID mice with de-glycosylated ricin-A-chain immunotoxins. Blood, 83, 466-475 (1994).